BCTX

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp. (BCTX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Profitability (D). The rating has held at C for 15 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -8.5
EV / EBITDA -0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -6.5%
Price Return 12M -66.1%
Catalyst Signal 0.00
Market Cap $28.8M
TTM Revenue N/A
Price / Sales N/A
ROE -214.8%

Historical Factor Score Progression

Held C for 15 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C+ (2.5) D (1.2) C+ (2.7) C+ (2.6) C (2.3)
2026-11-10 C+ (2.5) C+ (2.5) D (1.2) C+ (2.7) C+ (2.6) C (2.3)
2026-11-03 C+ (2.5) C+ (2.5) D (1.3) C+ (2.6) C+ (2.7) C (2.3)
2026-10-27 C+ (2.5) C+ (2.5) D (1.4) C+ (2.6) C+ (2.6) C (2.3)
2026-10-20 C+ (2.5) C+ (2.5) D (1.4) C (2.4) C+ (2.6) C (2.3)
Page 1 of 4